3692 (3692) News
Follow 3692 (3692) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Roche Partners With Hansoh in Deal That Could Exceed $15 Billion
Roche Holding entered a collaboration and licensing agreement with China's Hansoh Pharmaceutical Group. Hansoh will receive $400 million upfront and $110 million after a year, with eligibility for potential additional pa
MNA | Oct 19, 2026, 11:56 AM UTC
M
Hansoh Pharma Strikes Roche Drug Deal Worth Over $15 Billion
Hansoh Pharmaceutical said its units entered a collaboration and licensing deal with Roche covering antibody-drug conjugate programs. The deal is potentially worth more than $15 billion.
MNA | Oct 19, 2026, 10:27 AM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Weekly Recap: HS-10374 Phase—III success and Risvutatug NMPA priority
Hansoh Pharmaceutical Group Company Limited (HKEX:3692) advanced two programs: HS-10374 hit co-primary endpoints in a Phase III plaque psoriasis trial, while Risvutatug Rezetecan injection earned NMPA priority review for
NEWS | Sep 27, 2026, 11:01 PM UTC
L
Hansoh Pharmaceutical Says License Application Of Osteosarcoma Injection Accepted By NMPA
Hansoh Pharmaceutical Group Company Limited HKEX:3692
NEWS | Sep 24, 2026, 11:33 AM UTC
M
Hansoh says Risvutatug rezetecan added to NMPA priority review
REGULATION | Sep 22, 2026, 10:22 AM UTC
M
Hansoh says HS-10374 met co-primary endpoints in Phase III
Hansoh Pharmaceutical Group said its HS-10374 met the co-primary endpoints in its Phase III trial for plaque psoriasis.
EQUITY | Sep 21, 2026, 01:25 AM UTC
M
Hansoh’s HS-20197 gains NMPA approval for clinical trials
Hansoh Pharmaceutical says its HS-20197 for injection has received clinical trial approval from China’s NMPA.
REGULATION | Sep 16, 2026, 03:18 PM UTC
L
Hansoh says NMPA accepted biologics license application for HS-20093
Hansoh Pharmaceutical said China’s NMPA accepted its biologics license application for HS-20093.
EQUITY | Sep 02, 2026, 08:31 AM UTC
M
Hansoh net profit up 35.8% on double-digit revenue growth
Hansoh Pharmaceutical Group reported net profit surged 35.8% alongside double-digit revenue growth and strong innovative medicine sales.
EQUITY | Aug 26, 2026, 09:34 AM UTC